CALC net incomeQ2 2026-$7.65M
CALC net income was -$7.65M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.96M a year earlier. For the full fiscal 2025 it was -$29.56M, compared with -$13.70M in fiscal 2024.
CalciMedica Inc. (CALC) financials
For the twelve months ended Jun 30, 2026, CalciMedica Inc. reported -$21.24M of net income.
- Net income, TTM
- -$21.24M
- Free cash flow, TTM
- -$19.12M
- EPS, diluted, TTM
- -$1.36
- Cash
- $18.62M
- Market cap
- $9.3M
FY2019FY2025
FY2019FY2025
CALC revenue and earnings growth
CALC EPSQ2 2026-$0.45
CALC diluted EPS was -$0.45 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.40 a year earlier. For the full fiscal 2025 it was -$1.97, compared with -$1.22 in fiscal 2024.
CALC free cash flowQ2 2026-$4.62M
CALC free cash flow was -$4.62M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.67M a year earlier. For the full fiscal 2025 it was -$21.21M, compared with -$21.15M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $15.23M | $14.48M | $15.86M | $8.35M | $18.90M | $20.96M | $30.58M |
| Selling, general and admin | $7.89M | $9.73M | $22.22M | $5.84M | $17.04M | $8.87M | $6.92M |
| Operating income | -$23.12M | -$24.20M | -$38.08M | -$14.19M | -$35.95M | -$29.83M | -$37.50M |
| Interest expense | $1.42M | $0 | - | - | - | - | - |
| Pre-tax income | -$29.56M | -$13.70M | - | - | - | - | - |
| Income tax | $0 | $0 | $1.0K | $1.0K | - | - | - |
| Net income | -$29.56M | -$13.70M | -$34.36M | -$7.82M | -$35.82M | -$27.53M | -$37.04M |
| EPS, basic | -$1.97 | -$1.22 | -$7.66 | -$111.16 | -$1.69 | -$5.25 | -$33.41 |
| EPS, diluted | -$1.97 | -$1.22 | -$7.66 | -$111.16 | -$1.69 | -$5.25 | -$33.41 |
| Diluted shares | 15.0M | 11.2M | 4.5M | 82,245 | 21.2M | 6.6M | 1.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.52M | $7.93M | $5.53M | $1.33M | $13.36M | $33.42M | $15.87M |
| Short-term investments | $1.50M | $10.73M | $5.71M | $0 | $50.31M | $61.62M | $20.09M |
| Current assets | $13.53M | $19.66M | $11.61M | $1.73M | $67.08M | $99.24M | $36.27M |
| Total assets | $13.59M | $19.79M | $12.19M | $3.35M | $69.09M | $101.79M | $40.66M |
| Current liabilities | $3.78M | $3.68M | $4.03M | $4.78M | $4.06M | $7.00M | $12.25M |
| Total liabilities | $20.23M | $5.38M | $4.03M | $12.58M | $4.07M | $7.01M | $12.25M |
| Shareholders' equity | -$6.64M | $14.41M | $8.16M | -$71.30M | -$63.99M | $94.79M | -$102.95M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.18M | -$21.15M | -$25.73M | -$11.76M | -$31.50M | -$32.06M | -$31.21M |
| Capital expenditures | $28.0K | $8.0K | $78.0K | $4.0K | $488.0K | $1.02M | $605.0K |
| Free cash flow | -$21.21M | -$21.15M | -$25.81M | -$11.76M | -$31.99M | -$33.09M | -$31.82M |
| Investing cash flow | $9.55M | -$4.42M | $8.88M | -$4.0K | $10.75M | -$42.56M | -$20.62M |
| Financing cash flow | $15.21M | $27.97M | $20.90M | $8.48M | $695.0K | $92.17M | $54.87M |
| Stock-based compensation | $2.97M | $2.31M | $12.04M | $1.81M | $5.38M | $1.79M | $738.0K |
| Depreciation and amortization | - | - | $58.0K | $52.0K | - | - | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.10M | $3.48M | $3.11M | $3.85M | $4.05M | $4.22M | $3.83M | $3.55M | $4.16M | $2.94M | $2.78M | $2.77M |
| Selling, general and admin | $1.91M | $2.13M | $1.28M | $1.77M | $2.57M | $2.27M | $2.34M | $2.19M | $2.37M | $2.82M | $1.54M | $2.06M |
| Operating income | -$4.01M | -$5.61M | -$4.38M | -$5.62M | -$6.62M | -$6.50M | -$6.17M | -$5.74M | -$6.53M | -$5.77M | -$4.32M | -$4.83M |
| Interest expense | $325.0K | $319.0K | $325.0K | $326.0K | $324.0K | $447.0K | $0 | $0 | $0 | $0 | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.0K | $0 |
| Net income | -$7.65M | $4.98M | -$10.76M | -$7.80M | -$5.96M | -$5.04M | -$4.26M | -$5.62M | -$3.95M | $130.0K | -$4.15M | -$4.62M |
| EPS, basic | -$0.45 | $0.31 | -$0.69 | -$0.52 | -$0.40 | -$0.36 | -$0.37 | -$0.50 | -$0.36 | $0.01 | - | -$0.82 |
| EPS, diluted | -$0.45 | $0.30 | -$0.69 | -$0.52 | -$0.40 | -$0.36 | -$0.37 | -$0.50 | -$0.36 | $0.01 | - | -$0.82 |
| Diluted shares | 17.1M | 16.3M | - | 15.1M | 15.0M | 14.1M | - | 11.1M | 11.1M | 10.0M | - | 5.7M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $18.62M | $8.16M | $11.52M | $5.47M | $5.92M | $12.56M | $7.93M | $9.15M | $5.06M | $6.75M | $5.53M | $11.64M |
| Short-term investments | $0 | $0 | $1.50M | $8.61M | $12.04M | $12.07M | $10.73M | $5.45M | $14.08M | $18.95M | $5.71M | $2.95M |
| Current assets | $19.46M | $8.55M | $13.53M | $14.85M | $18.96M | $25.22M | $19.66M | $15.69M | $20.44M | $26.60M | $11.61M | $15.27M |
| Total assets | $19.50M | $8.61M | $13.59M | $14.91M | $19.08M | $25.35M | $19.79M | $16.21M | $21.05M | $27.13M | $12.19M | $15.85M |
| Current liabilities | $3.49M | $5.31M | $3.78M | $3.68M | $3.48M | $4.46M | $3.68M | $3.78M | $3.91M | $4.29M | $4.03M | $3.69M |
| Total liabilities | $13.99M | $9.71M | $20.23M | $15.18M | $12.98M | $14.46M | $5.38M | $7.18M | $7.21M | $9.89M | $4.03M | $3.69M |
| Shareholders' equity | $5.51M | -$1.10M | -$6.64M | -$268.0K | $6.10M | $10.89M | $14.41M | $9.03M | $13.84M | $17.25M | $8.16M | $12.16M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.62M | -$4.86M | -$4.85M | -$4.78M | -$6.67M | -$4.88M | -$4.97M | -$4.67M | -$6.79M | -$4.71M | -$3.61M | -$4.57M |
| Capital expenditures | $0 | $0 | $6.0K | $8.0K | $5.0K | $9.0K | $2.0K | $6.0K | $0 | $0 | $0 | $0 |
| Free cash flow | -$4.62M | -$4.86M | -$4.86M | -$4.79M | -$6.67M | -$4.89M | -$4.97M | -$4.67M | -$6.79M | -$4.71M | -$3.61M | -$4.57M |
| Investing cash flow | $42.0K | $1.50M | $7.15M | $3.51M | $134.0K | -$1.24M | -$5.17M | $8.75M | $5.10M | -$13.10M | -$2.68M | -$2.94M |
| Financing cash flow | $15.03M | $0 | $3.75M | $818.0K | -$102.0K | $10.74M | $8.92M | $16.0K | -$7.0K | $19.04M | $175.0K | $72.0K |
| Stock-based compensation | $540.0K | $561.0K | $622.0K | $625.0K | $1.18M | $549.0K | $632.0K | $781.0K | $486.0K | $414.0K | -$32.0K | $482.0K |
| Depreciation and amortization | - | - | - | - | - | - | - | - | - | - | $19.0K | $12.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.58 | 1.61 | 3.58 | 4.04 | 5.45 | 5.66 | 5.34 | 4.15 | 5.22 | 6.21 | 2.88 | 4.14 |
Source: XBRL data CalciMedica Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CALC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CALC | - | - | -$21.24M | - | $9.3M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
CALC FAQ
6 questionsIs CALC profitable?
No. CalciMedica Inc. reported a net loss of $21.24M for the twelve months ended Jun 30, 2026.How much cash and debt does CALC have?
CalciMedica Inc. reported $18.62M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CALC free cash flow?
CalciMedica Inc. generated -$19.12M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$19.11M less capital expenditures.What is CALC earnings per share?
Diluted earnings per share were -$1.36 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CALC last report financial results?
The latest statements here come from CalciMedica Inc.'s 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.Where does this CALC financial data come from?
Quantisnow builds these statements from the structured XBRL data CalciMedica Inc. files with the SEC. It is provided for information only and is not investment advice.